Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content

American Journal of Clinical Nutrition

Volumn 68, Issue 6 SUPPL., 1998, Pages

  Arjmandi, Bahram H ^a   Birnbaum, Roger ^b   Goyal, Noopur V ^b   Getlinger, Mary J ^b   Juma, Shanil ^b   Alekel, Lee ^b   Hasler, Clare M ^b   Drum, Melinda L ^b   Hollis, Bruce W ^b   Kukreja, Subhash C ^b  

^a OKLAHOMA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

Bone density; Bone formation rate; Isoflavones; Osteoporosis; Ovariectomy; Rats; Soy protein

Indexed keywords

ALKALINE PHOSPHATASE; CALCIFEDIOL; CALCITRIOL; CASEIN; HYDROXYPROLINE; ISOFLAVONE; SEX HORMONE; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN C; SOYBEAN PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE DENSITY; BONE TURNOVER; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; FEMUR; HORMONE DEFICIENCY; NONHUMAN; OVARIECTOMY; PROTEIN INTAKE; RAT; TIBIA;

ANIMALIA; GLYCINE MAX;

EID: 0031771538     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/68.6.1364S     Document Type: Conference Paper

References (30)

1. Riddle JM, Estes JW. Oral contraceptives in ancient and medieval times. Am Sci 1992;80:226-33.
2. Farmakalidis E, Hathcock JN, Murphy B. Oestrogenic potency of genistein and daidzein in mice. Food Chem Toxicol 1985;23:741-5.
3. Farnsworth NR, Bingel AS, Cordell GA, Grane FA, Fong HHS. Potential value of plants as sources of antifertility agents. J Pharm Sci 1975;64:535-98.
4. Love RR, Barden HS, Mazess RB, Epstein S, Chappel RJ. Effects of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;22:2585-8.
5. Baird DD, Umbach DM, Lansdell L, et al. Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 1995;80:1685-90.
6. Hutchins AM, Slavin JL, Lampe JW. Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 1995;95:545-51.
7. Gambacci M, Spinetti A, Cappagli B, et al. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women. J Endocrinol Invest 1985;16:333-7.
8. Gennari C. Metabolic and clinical effects of ipriflavone in established post-menopausal osteoporosis. Drugs Exp Clin Res 1991;2:97-104.
9. Yamazaki I. Effect of ipriflavone on the response of uterus and thyroid to estrogen. Life Sci 1986;38:757-64.
10. Yamazaki I, Kinoshita M. Calcitonin-secreting property of ipriflavone in the presence of estrogen. Life Sci 1986;38:1535-41.
11. Ettlinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term unopposed estrogen replacement therapy. Maturitas 1988;10:271-82.
12. Anderson JJ, Ambrose WW, Garner SC. Biphasic effects of genistein on bone tissue in the ovariectomized, lactating rat model. Proc Soc Exp Biol Med 1998;217:345-50.
13. Fanti O, Faugere MC, Gang Z, Schmidt J, Cohen D, Malluche HH. Systematic administration of genistein partially prevents bone loss in ovariectomized rats in a nonestrogen-like mechanism. Am J Clin Nutr 1998;68(suppl):1517S (abstr).
14. Arjmandi BH, Alekel L, Hollis BW, et al. Dietary soy protein prevents bone loss in an ovariectomized rat model of osteoporosis. J Nutr 1996;126:161-7.
15. Waynforth HB. Experimental and surgical technique in the rat. New York: Academic Press, 1980.
16. Barengolts EI, Lathon PV, Lindh FG. Progesterone antagonist RU 486 has bone sparing effects in ovariectomized rats. Bone 1995;17:21-5.
17. Kalu DN, Arjmandi BH, Liu CC, Salih MA, Birnbaum RS. Effects of ovariectomy and estrogen on the serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3. Bone Miner 1993;25:135-48.
18. 125I-labeled tracer. Clin Chem 1986;39:529-33.
19. Hollis BW. Assay of circulating 1,25-dihydroxy vitamin D involving a novel single cartridge extraction and purification procedure. Clin Chem 1986;32:2060-3.
20. Snedecor GW, Cochran WG. Statistical methods. Ames, Iowa: Iowa State University Press, 1967.
21. Chew V. Comparisons among treatment means in an analysis of variance. Hyattsvilte, MD: US Department of Agriculture, 1977.
22. Potter SM, Baum, JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(suppl):1375S-9S.
23. Omi N, Aoi S, Murata K, Ezawa I. Evaluation of the effect of soybean milk and soybean milk peptide on bone metabolism in the rat model with ovariectomized osteoporosis. J Nutr Sci 1994;40:201-11.
24. Martin PM, Horwitz KB, Ryan DS, McGuire WL. Phytoestrogen interaction with estrogen receptors in human breast cancer cells. Endocrinol 1978;103:1860-7.
25. Kalu DN, Salerno E, Liu CC, Echon R, Ray M, Garza-Zapata M, and Hollis BW. A comparative study of the action of tamoxifen, estrogen and progesterone in ovariectomized rat. Bone Miner 1991;15:109-24.
26. Feldman S, Minne HW, Parvizi S, Pfeifer M, Lempert UG, Bauss Zeigler R. Antiestrogen and antiandrogen administration reduce bone mass in the rat. Bone Miner 1989;7:245-54.
27. Miksicek RJ. Commonly occurring plant flavonoids have estrogenic activity. Mol Pharmacol 1993;44:37-43.
28. Shutt, DA. Interaction of genistein with oestradiol in the reproductive tract of the ovariectomized mouse. J Endocrinol 1967;37:231-2.
29. Zava DT, Duwe G. Estrogenic and antiproliferative properties of genistein and other flavonoids in human breast cancer cells in vitro. Nutr Cancer 1997;27:31-40.
30. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994;21:113-31.